TABLE 3.
Representative Gene Expression Changes in rAAV-CNTF-Treated rds Retina*
| Potential or Known Function |
Gene Name | GenBank Acc. Number |
Ratios (Mean ± SEM)† (rAAV-CNTF inj./Non-inj.) |
|---|---|---|---|
| Phototransduction | S-opsin | NM 007538 | 0.40 ± 0.11 |
| Cone transducin alpha-subunit (Gnat2) | NM 008141 | 0.51 ± 0.01 | |
| Rod phosphodiesterase b (pdeb) | NM 008806 | 0.67 ± 0.09 | |
| Rod transducin beta1-subunit (Gnb1) | NM 008142 | 0.39 ± 0.13 | |
| Guanylate cyclase activator 1α (Guca1a) | NM 008189 | 0.47 ± 0.12 | |
| Retinal structure and Function | Crumbs homolog 1 (crb1) | NM 133239 | 0.66 ± 0.07 |
| Elongation of long chain fatty acids, ELOVL6 | BC 100576 | 0.58 ± 0.08 | |
| Synapsin II (Syn2) | NM 013680 | 0.66 ± 0.02 | |
| Retinitis pigmentosa 9 homolog (RP9) | BC 048480 | 0.55 ± 0.07 | |
| Retinol dehydrogenase 11 (Rdh11) | NM 021557 | 0.60 ± 0.001 | |
| Interphotoreceptor matrix proteoglycan 1 (Impg1) | NM 022016 | 1.47 ± 0.10 | |
| Nestin | NM 016701 | 1.71 ± 0.13 | |
| GFAP | NM 010277 | 2.60 ± 0.98 | |
| Chromatin | Nucleolin (Ncl) | NM 010880 | 0.64 ± 0.05 |
| Retinoblastoma binding protein 9 (Rbbp9) | NM 015754 | 0.59 ± 0.10 | |
| Early growth response 1 (egr1) | NM 007913 | 0.45 ± 0.03 | |
| Histone deacetylase 11 (Hdac11) | NM 144919 | 1.28 ± 0.02 | |
| Transcription | Cone rod homeobox gene (Crx) | NM 007770 | 0.71 ± 0.08 |
| Neural retina leucine zipper gene (Nrl) | NM 008736 | 0.66 ± 0.08 | |
| Trans-acting transcription factor 1 (SP1) | NM 013672 | 0.59 ± 0.02 | |
| Kruppel-like factor 4 (Klf4) | NM 010637 | 0.48 ± 0.08 | |
| Interleukine enhancer binding factor 2 (Ilf2) | NM 026374 | 0.53 ± 0.07 | |
| Hairy/enhancer-of-split related with YRPW2 (Hey2) | NM 013904 | 1.77 ± 0.07 | |
| Cell death/survival | Programmed cell death protein 7 (pdcd7) | BC 022772 | 0.66 ± 0.07 |
| Programmed cell death protein 4 (pdcd4) | BC 055739 | 0.61 ± 0.04 | |
| Bcl2-like 10 (Bcl2110) | NM 013479 | 1.54 ± 0.06 | |
| Cell cycle | Annexin A7 (Anxa7) | NM 009674 | 0.62 ± 0.08 |
| Transducer of ERBB2, 2 (Tob2) | NM 020507 | 0.66 ± 0.04 | |
| Wee 1 homolog | NM 009516 | 1.68 ± 0.20 | |
| G1 to phase transition 1 (Gspt1) | NM 146066 | 1.57 ± 0.12 | |
| Neuroblastoma myc-related oncogene 1 (Nmyc) | NM 008709 | 1.56 ± 0.10 | |
| Cyclin-dependent kinase-like 3 (Cdkl3) | NM 153785 | 1.35 ± 0.07 | |
| Signal transduction | Janus kinase 1 (Jak1) | NM 146145 | 0.65 ± 0.03 |
| Ephrin B2 (Efnb2) | NM 010111 | 0.48 ± 0.07 | |
| SH2 domain binding protein 1 (Sh2bp1) | BC 071247 | 0.56 ± 0.06 | |
| Cellular repressor of E1A-stimulated genes (Creg1) | NM 011804 | 0.67 ± 0.06 | |
| Protein tyr phosphatase, receptor type, E (Ptpre) | NM 011212 | 0.59 ± 0.03 | |
| Protein tyr phosphatase, non-receptor 21 (Ptpn21) | NM 011877 | 0.69 ± 0.03 | |
| STAT1 | NM 009283 | 1.65 ± 0.14 | |
| Smoothened (Smo) | BC 048091 | 0.65 ± 0.02 | |
| STAT3 | NM 011486 | 1.60 ± 0.40 | |
| MAPK1 | NM 011949 | 1.78 ± 0.25 | |
| MAPK-interacting ser/threo kinase 1 (Mknk1) | BC 021369 | 1.48 ± 0.12 | |
| Serum/glucocorticoid regulated kinase 2 (Sgk2) | NM 013731 | 1.47 ± 0.14 | |
| Neuropilin 1 (Nrp1) | NM 008737 | 1.52 ± 0.17 | |
| Growth hormone receptor (Ghr) | NM 010284 | 1.65 ± 0.36 | |
| Platelet derived growth factor, alpha (Pdgfa) | NM 008808 | 1.66 ± 0.22 | |
| Chemokine (C-X-C motif) ligand 13 (Cxcl13 | NM 018866 | 2.84 ± 0.37 | |
| Immunoresponse | Complement component factor I (Cfi) | NM 007686 | 1.42 ± 0.06 |
| Complement component 4 (C4) | M11789 | 1.66 ± 0.66 |
*
A representative 50 genes with transcript levels altered by more than 25% after rAAV-CNTF treatment are shown. Genes with decreased transcripts are listed before genes with increased transcripts in each functional category.
†
The ratios of rAAV-CNTF injected rds retina and control noninjected rds retina represent values from three or four independent array experiments (mean ± SEM).